Migraine Genetics: Unlocking a Cure for Migraine
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
Key Questions
- What were the results from the largest global genetic migraine study?
- What migraine genes have recently been discovered?
- How does genetics play a role in personalised medicine?
Interview Notes
Find more about Lyn Griffiths and her work here:

Lyn Griffiths, PhD
Executive Director
Institute of Health and Biomedical Innovation
Professor Lyn Griffiths is the executive director of the Institute of Health and Biomedical Innovation, the largest interdisciplinary research institute at Queensland University of Technology. An active and respected molecular geneticist with more than 28 years of experience studying human complex gene disorders with specific expertise in the human gene mapping and gene expression analysis in migraine, cardiovascular disease and several types of cancer. Professor Griffiths leads the Genomics Research Centre in which the main focus of research is the identification of genes involved in common human disorders and the translation of this research into new diagnostics and therapeutics.
Professor Griffiths’ own genetics research has appeared in more than 350 peer-reviewed international journals and led to diagnostic breakthroughs for several neurogenetic disorders, including familial migraine, ataxia, epilepsy and hereditary stroke. A fellow of the Queensland Academy of Arts and Science, Professor Griffiths has also established several significant international collaborations with the Texas Biomedical Research Institute, Oxford University, University of Vienna, the Italian National Research Council, the MS ANZ Gene Consortium and the International Migraine Genetics Consortium.

Unlock full access to the entire 2017 Summit, including:
- 30+ Expert interviews with audio clips and transcripts
- Unlimited streaming and downloads
- Lifetime access with no annual fee